全面等位基因分型在关键药物基因中降低不同人群的残余临床风险
该研究基于超过86,000名个体的短读长测序数据,构建了Helix PGx数据库,覆盖CYP2C9、CYP2C19、CYP2D6和CYP4F2的星号等位基因、基因型及代谢表型频率。研究发现CYP2D6等位基因多样性最高,且超过90%的队列在四个药物基因中携带至少一个高风险变异;结合超过30,000人的处方记录,预计标准筛查这4个基因可能影响近半数一般人群。
要点
- Helix PGx数据库开放提供CYP2C9、CYP2C19、CYP2D6和CYP4F2的等位基因和表型频率。
- CYP2D6结构变异检测准确率达98%,且新发功能缺失变异占比36%。
- 超过90%的个体携带至少一个高风险药物基因变异,筛查可能影响近半数人群。
核心结论
- 全面等位基因分型可识别关键药物基因中的高风险变异,降低不同人群的残余临床风险。
研究设计与样本
- 基于Helix DNA Discovery Project中超过86,000名无亲缘关系个体的短读长测序数据构建数据库。
- 使用经临床验证的流程注释等位基因,CYP2D6结构变异检测准确率为98%。
主要发现
- CYP2D6等位基因多样性高于其他基因,表现为低频星号等位基因长尾及36%的新发预测功能缺失变异。
- 许多频率低于0.1%的罕见等位基因在一个或多个非欧洲遗传 ancestry 亚组中频率高10倍。
- 超过90%的队列在四个药物基因中携带至少一个高风险变异。
- 基于超过30,000名Healthy Nevada Project个体的处方记录,标准筛查这4个基因可能影响近半数一般人群。
临床怎么用
- 可参考Helix PGx数据库进行CYP2C9、CYP2C19、CYP2D6和CYP4F2的等位基因频率查询和代谢表型预测。
- 对这四个药物基因进行标准筛查可能识别近半数一般人群中的高风险个体,辅助处方决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic-guided pharmaceutical prescribing is increasingly recognized as an important clinical application of genetics. Accurate genotyping of pharmacogenomic (PGx) genes can be difficult, owing to their complex genetic architecture involving combinations of single-nucleotide polymorphisms and structural variation. Here, we introduce the Helix PGx database, an open-source star allele, genotype, and resulting metabolic phenotype frequency database for CYP2C9, CYP2C19, CYP2D6, and CYP4F2, based on short-read sequencing of >86,000 unrelated individuals enrolled in the Helix DNA Discovery Project. The database is annotated using a pipeline that is clinically validated against a broad range of alleles and designed to call CYP2D6 structural variants with high (98%) accuracy. We find that CYP2D6 has greater allelic diversity than the other genes, manifest in both a long tail of low-frequency star alleles, as well as a disproportionate fraction (36%) of all novel predicted loss-of-function variants identified. Across genes, we observe that many rare alleles (<0.1% frequency) in the overall cohort have 10 times higher frequency in one or more subgroups with non-European genetic ancestry. Extending these PGx genotypes to predicted metabolic phenotypes, we demonstrate that >90% of the cohort harbors a high-risk variant in one of the four pharmacogenes. Based on the recorded prescriptions for >30,000 individuals in the Healthy Nevada Project, combined with predicted PGx metabolic phenotypes, we anticipate that standard-of-care screening of these 4 pharmacogenes could impact nearly half of the general population.
引用
- Luo S, Jiang R, Grzymski JJ, et al. Comprehensive Allele Genotyping in Critical Pharmacogenes Reduces Residual Clinical Risk in Diverse Populations. Clin Pharmacol Ther. 2021. PMID: 33930192. doi:10.1002/cpt.2279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。